Marker Therapeutics Inc expected to post a loss of 22 cents a share - Earnings Preview

Reuters03-21

Marker <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Inc <mrkr.oq> expected to post a loss of 22 cents a share - Earnings Preview </mrkr.oq>

Marker Therapeutics Inc MRKR.OQ MRKR.O is expected to report resultson March 24 (estimated) for the period ending December 31 2024
The Houston Texas-based company is expected to report revenue of $3.982 million, according to the mean estimate from 3 analysts, based on LSEG data.
LSEG's mean analyst estimate for Marker Therapeutics Inc is for a loss of 22 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Marker Therapeutics Inc is $8.00, above its last closing price of $1.25.

This summary was machine generated March 21 at 11:49 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2521840047?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-21 19:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2521840047","market":"nz","top_or_hot":-1,"title":"Marker Therapeutics Inc  expected to post a loss of 22 cents a share - Earnings Preview","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Marker <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <mrkr.oq> expected to post a loss of 22 cents a share - Earnings Preview </mrkr.oq></title></head><body><ul><li><p>Marker Therapeutics Inc <span>MRKR.OQ</span> <span>MRKR.O</span> is expected to report resultson March 24 (estimated) for the period ending December 31 2024</p></li><li><p>The Houston Texas-based  company is expected to report revenue of $3.982 million, according to the mean estimate from 3 analysts, based on LSEG data.</p></li><li><p>LSEG's mean analyst estimate for Marker Therapeutics Inc is for a loss of 22 cents per share. </p></li><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\"  </p></li><li><p>The mean earnings estimate of analysts was unchanged in the last three months. </p></li><li><p>Wall Street's median 12-month price target for Marker Therapeutics Inc is $8.00, above its last closing price of $1.25. </p></li></ul><p>This summary was machine generated March 21 at 11:49 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Marker Therapeutics Inc  expected to post a loss of 22 cents a share - Earnings Preview</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMarker Therapeutics Inc  expected to post a loss of 22 cents a share - Earnings Preview\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-03-21 19:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Marker <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <mrkr.oq> expected to post a loss of 22 cents a share - Earnings Preview </mrkr.oq></title></head><body><ul><li><p>Marker Therapeutics Inc <span>MRKR.OQ</span> <span>MRKR.O</span> is expected to report resultson March 24 (estimated) for the period ending December 31 2024</p></li><li><p>The Houston Texas-based  company is expected to report revenue of $3.982 million, according to the mean estimate from 3 analysts, based on LSEG data.</p></li><li><p>LSEG's mean analyst estimate for Marker Therapeutics Inc is for a loss of 22 cents per share. </p></li><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\"  </p></li><li><p>The mean earnings estimate of analysts was unchanged in the last three months. </p></li><li><p>Wall Street's median 12-month price target for Marker Therapeutics Inc is $8.00, above its last closing price of $1.25. </p></li></ul><p>This summary was machine generated March 21 at 11:49 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRKR","symbol_name":"Marker Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250321:nL8N3Q40VN:1","article_id":"2521840047","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2521840047","pubTimestamp":1742557748,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Marker Therapeutics Inc  expected to post a loss of22cents a share - Earnings Preview Marker Therapeutics Inc MRKR.OQ MRKR.O is expected to report resultson March 24 (estimated) for the period ending ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"MRKR":"Marker Therapeutics, Inc."},"translate_title":"Marker Therapeutics Inc预计每股亏损22美分-收益预览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRKR":0.9},"content_text":"Marker Therapeutics Inc  expected to post a loss of 22 cents a share - Earnings Preview Marker Therapeutics Inc MRKR.OQ MRKR.O is expected to report resultson March 24 (estimated) for the period ending December 31 2024The Houston Texas-based  company is expected to report revenue of $3.982 million, according to the mean estimate from 3 analysts, based on LSEG data.LSEG's mean analyst estimate for Marker Therapeutics Inc is for a loss of 22 cents per share. The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\"  The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for Marker Therapeutics Inc is $8.00, above its last closing price of $1.25. This summary was machine generated March 21 at 11:49 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2521840047","isCrawlerRequest":true}